Label: LACTULOSE solution
Contains inactivated NDC Code(s)
NDC Code(s): 60432-037-08, 60432-037-32
- Packager: Morton Grove Pharmaceuticals, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated November 4, 2019
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- SPL UNCLASSIFIED SECTION
Lactulose solution is a synthetic disaccharide in solution form for oral administration. Each 15 mL of lactulose contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g or less of other sugars). Also contains water. The pH range is 4.8 to 6.0.
Lactulose solution is a colonic acidifier which promotes laxation.
The chemical name for lactulose is 4-0-β-D-galactopyranosyl-D-fructofuranose. It has the following structural formula:
The molecular weight is 342.30. It is freely soluble in water.
Lactulose is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.
Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce the desired bowel movement.
Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.
- INDICATIONS AND USAGE
A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO2 as an additional safeguard may be pursued but is considered to be a redundant measure.
Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL), it should be used with caution in diabetics.
Information for Patients
In the event that an unusual diarrheal condition occurs, contact your physician.
Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.
Results of preliminary studies in humans and rats suggest that non-absorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.
Carcinogenesis, Mutagenesis, Impairment of Fertility
There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.
There are no known animal data on long-term potential for mutagenicity.
Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.
In studies in mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.
Pregnancy Category B
Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman.
Precise frequency data are not available.
Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.
Nausea and vomiting have been reported.
To report SUSPECTED ADVERSE REACTIONS, contact Wockhardt USA, LLC, at 1-800-445-4290 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Signs and Symptoms
There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.
DOSAGE AND ADMINISTRATION
The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.
NOTE: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
Lactulose Solution USP 10 g/15 mL is a colorless to yellow, unflavored solution available in the following container sizes:
8 fl oz (237 mL) bottles (NDC 60432-037-08)
1 Quart (946 mL) bottles (NDC 60432-037-32)
Store at 20 ° to 25 °C (68 ° to 77 °F) [see USP Controlled Room Temperature]. Do Not Freeze
Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action.
Prolonged exposure to temperatures above 30 °C (86 °F) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use.
Prolonged exposure to freezing temperatures may cause change to a semisolid, too viscous to pour. Viscosity will return to normal upon warming to room temperature.
Dispense in original container or in a tight, light-resistant container as defined in the USP, with a child-resistant closure.
To The Pharmacist: When ordering this product, include the product number (or NDC) in the description.
Product No.: 8037
Manufactured For: Morton Grove Pharmaceuticals, Inc.
Morton Grove, IL 60053
Packaged By: Morton Grove Pharmaceuticals, Inc.
Morton Grove, IL 60053
Distributed By: Wockhardt USA, LLC
Parsippany, NJ 07054
A50-8037-08 REV. 05-18
- PACKAGE LABEL PRINCIPAL DISPLAY PANEL Bottle Label
INGREDIENTS AND APPEARANCE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:60432-037 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LACTULOSE (UNII: 9U7D5QH5AE) (LACTULOSE - UNII:9U7D5QH5AE) LACTULOSE 10 g in 15 mL Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:60432-037-08 237 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/14/1996 2 NDC:60432-037-32 946 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/14/1996 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA074602 11/14/1996 Labeler - Morton Grove Pharmaceuticals, Inc. (801897505) Registrant - Morton Grove Pharmaceuticals, Inc. (801897505) Establishment Name Address ID/FEI Business Operations Morton Grove Pharmaceuticals, Inc. 801897505 ANALYSIS(60432-037) , LABEL(60432-037) , MANUFACTURE(60432-037) , PACK(60432-037)